CRENESSITY® (crinecerfont) is the first and only FDA-approved treatment for people 4+ years old with classic congenital adrenal hyperplasia (CAH). CRENESSITY controls androgens, allowing for lower steroid doses. CRENESSITY is used together with steroids.
CRENESSITY was studied in the largest clinical trial program ever for a classic CAH treatment. In the adult and pediatric studies, lowering androgen levels with CRENESSITY enabled reduced steroid doses.
IN ADULTS (18 years or older)
17-OHP=17-hydroxyprogesterone.
- *Androstenedione levels were reduced by 299 ng/dL in adults taking CRENESSITY compared with an increase of 46 ng/dL with placebo. At the beginning of the study, adults had an average androstenedione level of 620 ng/dL.
- †17-OHP levels were reduced by 5994 ng/dL in adults taking CRENESSITY compared with a reduction of 156 ng/dL with placebo. At the beginning of the study, adults had an average 17-OHP level of 9467 ng/dL.
Steroid doses were lowered under careful supervision of doctors. CRENESSITY does not address cortisol deficiency. People taking CRENESSITY should continue taking steroids to replace missing cortisol.
- ‡Adults treated with CRENESSITY were able to reduce their steroid dose by 27% from the beginning of the study compared with 10% for placebo. At the beginning of the study, adults were taking an average of 32 mg/day hydrocortisone.
- §The cortisol replacement range was less than or equal to 11 mg/m2/day hydrocortisone (or equivalent doses for prednisone or dexamethasone). For someone who is 5’8″ and 150 lb, 11 mg/m2/day equates to 20 mg/day hydrocortisone. A total of 18% of adults taking placebo were able to lower their steroid doses to the range needed just to replace cortisol while androgen levels stayed the same or improved.
Learn more about the CRENESSITY study in adults at CRENESSITY.com/why-crenessity.
Watch Susan explain how CRENESSITY helped her go from being overmedicated to having a more balanced treatment approach:
Susan has classic CAH and is taking CRENESSITY. She was compensated by Neurocrine for sharing her story.
CRENESSITY has a demonstrated safety profile
- In the CAHtalyst™ Adult clinical study, 2 patients (out of 122) taking CRENESSITY experienced adrenal crisis. No patients on placebo experienced adrenal crisis; however, one did experience adrenal insufficiency
- Tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain were the most common side effects in adults taking CRENESSITY
- Most side effects were temporary and mild to moderate in severity¶
- 96% of adults taking CRENESSITY completed the 24-week study
After the placebo period of the study ended, 174 of the 182 adults (96%) chose to continue in the study, with all participants taking CRENESSITY.
Adrenal insufficiency and crisis are risks of living with CAH that CRENESSITY does not address and can occur when your steroid dose is too low.
Acute adrenal crisis can occur in patients with underlying adrenal insufficiency, especially in situations associated with increased cortisol need, such as acute illness, serious trauma, or surgical procedures.
Please talk to your doctor about how to manage your steroid dosing while taking CRENESSITY.
Want to talk to your doctor about the potential benefits of CRENESSITY for you? Visit CRENESSITY.com/videos-resources to create a customizable doctor discussion guide to use at your next appointment.
- ¶A total of 3% of patients treated with CRENESSITY and no placebo-treated patients discontinued treatment because of adverse reactions of restlessness, apathy, dyspepsia, nausea, and vomiting.